<?xml version="1.0" encoding="UTF-8"?>
<p>For JEV, several licensed inactivated and live attenuated vaccines, including Ixiaro (inactivated vaccine) and JE-CVax (Imojev; YFV-17D-based chimeric live attenuated vaccine [c-LAV]), are available (
 <xref rid="B10" ref-type="bibr">10</xref>, 
 <xref rid="B11" ref-type="bibr">11</xref>). Another YFV-17D-based tetravalent c-LAV, namely, against dengue (CYD-TDV, Dengvaxia), has reached marketing licensure and is being introduced in some countries/regions. However, there are serious concerns related to the use of this vaccine in dengue virus-seronegative individuals, mainly because of aggravation of dengue disease by preexisting antibodies (antibody-dependent enhancement [ADE]) of DENV infection (
 <xref rid="B12" ref-type="bibr">12</xref>
 <xref ref-type="bibr" rid="B13">â€“</xref>
 <xref rid="B14" ref-type="bibr">14</xref>).
</p>
